ClinicalTrials.gg
DrugBiological

Botensilimab clinical trials

Also written AGEN1181.

studies test it
30
open now
14
in phase 3
2
first study started
2019

How each study uses botensilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the botensilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Botensilimab
28
Anti-CTLA-4 Monoclonal Antibody AGEN1181
8

Development codes

AGEN1181
18

Studies by the year they started

28 studies that test it; most in 2025 (8); 2 more planned to start later

Studies that test botensilimab, by start year
YearStudies
20191
20201
20222
20236
20246
20258
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
6
Phase 2
22
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 4 · Other 26

City of Hope Medical Center (5) · Agenus Inc. (4) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · Northwestern University (1) · Bruno Bockorny (1) · Immune Oncology Research Institute (1) · University of Colorado, Denver (1)

Often tested with

Tested in the same studies.

Balstilimab (26) · Dalutrafusp alfa (1) · Zalifrelimab (1) · Trastuzumab deruxtecan (1) · Durvalumab (1) · Panitumumab (1) · Sotorasib (1) · Vorbipiprant (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8

Studies that test botensilimab.

Studies

Open first, then newest update. How each study uses botensilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 30

See all 30 studies that test botensilimab →

Given beside what is tested · 7 — botensilimab is usual care or a partner of the new treatment

Codes

What other systems call botensilimab · ClinicalTrials.gg INT014370

  • UNII (FDA) 1Z5YC3ME5NBOTENSILIMABOne source FDA
  • NCI Thesaurus C158557BotensilimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.